Brief: Lidds Announces Positive Topline Results From Phase I Study

Lidds AB

29/12/2021 10:09

Dec 29 (Reuters) - Lidds AB  LIDDS.ST :
    * LIDDS ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE I
DOSE-ESCALATING STUDY OF NANOZOLID®-FORMULATED DOCETAXEL
    * RESULTS SUPPORT FURTHER DEVELOPMENT OF
NANOZOLID®-DOCETAXEL
    * STUDY MEETS ITS PRIMARY ENDPOINT OF BEING SAFE AND
TOLERABLE
    * SYSTEMIC EXPOSURE OF DOCETAXEL AFTER TREATING SOLID TUMORS
WITH
NANOZOLID®-DOCETAXEL IS LOW AND THAT STUDY DEMONSTRATED ACTIVITY
IN BOTH INJECTED LESIONS AND IN SYSTEMIC INFLAMMATORY MARKERS
    * IN ADDITION TO MEETING PRIMARY ENDPOINT, WE ALSO SEE SIGNS
OF
IMMUNE ACTIVATION BY AN UPREGULATION OF KEY IMMUNE REGULATING
MOLECULES

Source text for Eikon:  ID:nGNE7bg4R7 
Further company coverage:  LIDDS.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))